Monographie - Deferoxamine mesylate - Stabilis 4.0

Son güncelleme :
19/11/2024

Şelatör

Deferoxamine mesylate

Enjeksiyon

Çözeltilerin stabilitesi

Karışımlardaki stabilitesi

Stabiliteyi etkileyen faktörler

Uyumluluk

Uygulama yöntemi

Kaynaklar

pdf

Kimyasal yapı

Ticari isim

Ticari isim

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Deferoxamina	İspanya
Deferoxamine mesylate	Amerika Birleşik Devletleri, Kanada
Deferoxaminmesilat	Almanya
Desferal	Almanya, Amerika Birleşik Devletleri, Arjantin, Avustralya, Avusturya, Belçika, Büyük Britanya, Danimarka, Fas, Finlandiya, Fransa, Hindistan, Hollanda, İran, İrlanda, İsveç, İsviçre, İtalya, İzlanda, Kanada, Kolombiya, Lüksemburg, Macaristan, Malezya, Meksika, Mısır, Norveç, Polonya, Portekiz, Romanya, Şili, Suudi Arabistan, Tunus, Türkiye, Venezuela, Yunanistan
Desferin	Danimarka, İspanya
Desferioxamine mesilate	Büyük Britanya
Desfonak	İran
PMS desferoxamine	Kanada
Talifer	Meksika

Kaynaklar

Enjeksiyon

Kaynaklar : Deferoxamine mesylate

	tip	yayın
5	Dergi	Stiles ML, Allen LV Jr, Prince SJ. Stability of deferoxamine mesylate, floxuridine, fluorouracil, hydromorphone hydrochloride, lorazepam, and midazolam hydrochloride in polypropylene infusion-pump syringes. Am J Health-Syst Pharm 1996 ; 53: 1583-1588.
604	Laboratuar	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
960	Dergi	Koren G, Tesoro A, Leeder JS, Bentur Y, Olivieri N. Stability of aqueous solutions of deferoxamine. Can J Hosp Pharm 1990 ; 43: 57-60.
1669	Dergi	Hayes DM, Reilly RM, Lee MMC. The pharmaceutical stability of deferoxamine mesylate. Can J Hosp Pharm 1994 ; 47: 9-14.
2156	Dergi	Kane MP, Bailie GR, Moon DG, Siu I. Stability of deferoxamine peritoneal dialysate solutions. Perit Dial Int 1994 ; 14: 396-398.
3671	Laboratuar	Deferoxamine - Résumé des caractéristiques du produit Teva UK Ltd 2016
3728	Dergi	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.

Mentions Légales